Our website uses cookies to enhance and personalize your experience and to display advertisements (if any). Our website may also include third party cookies such as Google Adsense, Google Analytics, Youtube. By using the website, you consent to the use of cookies. We have updated our Privacy Policy. Please click the button to view our Privacy Policy.

Human surfaceome mapped by AI highlights 1,108 potential drug targets missing from databases

Human surfaceome mapped by AI highlights 1,108 potential drug targets missing from databases
Contents
  1. Databases that disagree
  2. How the tool works
  3. An example: the KLK2 protein
  4. An open resource
  5. References

Over 65% of approved medicines function by attaching to proteins on the exterior of human cells, although primary biological databases fail to agree on their actual presence. The Deliverome Project, which operates as an open research initiative, applied artificial intelligence to analyze existing literature and construct a comprehensive map of the human surfaceome, representing the complete array of cell surface proteins.

The map flags 1,108 candidate proteins that are missing from all five major reference databases but are supported by published studies. The findings were posted in October 2026 as a preprint on bioRxiv, so they have not yet been peer reviewed, and the proteins are candidates rather than confirmed targets.

Databases that disagree

The team compared five databases: UniProt, GO CC, the Human Protein Atlas, the Cell Surface Protein Atlas and SURFY. Together they list 5,546 surface proteins, but all five agree on only 188, according to the Hertz Foundation.

How the tool works

Co-founders Becca Carlson and Bobby Hollingsworth built an AI agent using the Claude Sonnet 4.6 model. The agent reviews the scientific literature to determine whether a protein sits on the cell surface.

On SurfaceBench, a hand-labeled collection consisting of 147 proteins, the agent achieved a 95.7% classification accuracy, whereas UniProt, which stood out as the top-performing database, reached roughly 90%.

An example: the KLK2 protein

All five databases classify the protein KLK2 as absent from the cell surface. However, research has found a membrane-anchored form enriched in prostate cancer, and an experimental therapy targeting it is in Phase 3 trials. Deliverome classifies KLK2 as able to appear on the surface under certain conditions.

An open resource

The map is free to explore in Open View, an interactive tool that showcases each protein next to its corresponding research. Additionally, the initiative provides a public API alongside open-source code.

“My hope is that this will help people develop drugs that are more diverse and serve more patients and more indications,” said Carlson, a 2017 Hertz Fellow and the project’s co-CEO.

Deliverome launched on May 27, 2026, backed by $5 million in seed capital originating from the Astera Institute. Operating as a Focused Research Organization, it utilizes a framework tailored to roll out public research instruments inside roughly half a decade. Investigators affiliated with Coral Biosciences additionally contributed as co-authors on the preprint.

References

By Ava Martinez

You may also like